Explore how Agilent's (A) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Agilent Technologies is upgraded to Buy after a strong Q3 2026, with revenue up 8% and EPS up 18% YoY. All three segments posted robust growth, notably Life Sciences and Diagnostics, which saw operating margin jump nearly 600 bps to 23.5%. Guidance for Q4 and FY26 implies continued momentum, with management projecting 6.5–7.5% revenue growth and 8.5% EPS growth for Q4.
Agilent Technologies, Inc. (A) Q3 2026 Earnings Call Transcript
| Professional Services Industry | Industrials Sector | Padraig McDonnell CEO | XMUN Exchange | US00846U1016 ISIN |
| US Country | 18,000 Employees | 30 Jun 2026 Last Dividend | 3 Nov 2014 Last Split | - IPO Date |
Agilent Technologies, Inc. stands as a global provider offering application-focused solutions primarily to the life sciences, diagnostics, and applied chemical sectors. The company propagates its mission across three distinct segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab, ensuring a broad spectrum of scientific research, diagnostic, and analytical needs are met worldwide. Since its establishment in 1999, Agilent has cemented its headquarters in Santa Clara, California, from where it orchestrates its global operations, offering an expansive portfolio through direct sales, distributors, resellers, and electronic commerce frameworks.